Advertisement

An Evidence-Based Perspective of Curcuma Longa (Turmeric) for Cancer Patients

  • G. Bar-Sela
  • M. Schaffer
Chapter
Part of the Evidence-based Anticancer Complementary and Alternative Medicine book series (ACAM)

Abstract

Curcumin [diferuloylmethane (C21H20O6)], a polyphenol, is an active principle of the perennial herb Curcuma longa (commonly known as turmeric) and derived from the roots (rhizomes) of the plant. Traditionally, turmeric has been used as a foodstuff and a cosmetic and has been a component of Indian Ayurvedic medicine since 1900 BC. As a medicine, curcumin is used mainly for various allergic and inflammatory respiratory conditions, as well as for liver disorders, anorexia, rheumatism and wound healing. These folk medicinal indications are still popular and widely used as alternative agents in many parts of Southeast Asia. Extensive research over the last half-century has revealed important functions of curcumin. In vitro and in vivo research has shown curcumin’s various activities, such as anti-inflammation, cytokines release, antioxidation, immunomodulation, enhancing of the apoptotic process, and anti-angiogenic properties. Curcumin has also been shown to be a mediator of chemo-resistance and radio-resistance. The anticancer effect has been seen in a few clinical trials, mainly as a chemo-prevention agent in colon and pancreatic cancer and in other high-risk premalignant conditions. Some clinical studies on healthy volunteers revealed a low bioavailability, casting doubt on the use of curcumin only as a food additive. In cancer, clinical studies have not shown significant results but the data is richer than in non-malignant conditions. Unlike chemo-therapeutic agents, including those isolated from plants, curcumin is a part of our daily food habit and its use in large quantities since ancient times has proved that it is a safe product. While the pre-clinical data is broad, clinical studies are scarce, although some are on-going. The possible clinical efficacy of this treatment as a chemo-preventive or chemo-therapeutic agent is still to be proven. This chapter ranges from a historical description to pre-clinical data and focuses on existing clinical evidence.

Keywords

Pancreatic Cancer Familial Adenomatous Polyposis Cervical Intraepithelial Neoplasia Advanced Pancreatic Cancer Oral Leukoplakia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akpolat, M., Kanter, M., & Uzal, M. C. (2009). Protective effects of curcumin against gamma radiation-induced ileal mucosal damage. Archives of Toxicology, 83, 609–617.PubMedCrossRefGoogle Scholar
  2. Ammon, H. P., & Wahl, M. A. (1991). Pharmacology of curcuma longa. Planta Medica, 57, 1–7.PubMedCrossRefGoogle Scholar
  3. Anand, P., Nair, H. B., Sung, B., et al. (2010). Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochemical Pharmacology, 79, 330–338.PubMedCrossRefGoogle Scholar
  4. Anand, P., Thomas, S. G., Kunnumakkara, A. B, et al. (2008). Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochemical Pharmacology, 76, 1590–1611.PubMedCrossRefGoogle Scholar
  5. Atsumi, T., Fujisawa, S., & Tonosaki K. (2005). Relationship between intracellular ROS production and membrane mobility in curcumin- and tetrahydrocurcumin-treated human gingival fibroblasts and human submandibular gland carcinoma cells. Oral Diseases, 11, 236–242.PubMedCrossRefGoogle Scholar
  6. Bar-Sela, G., Epelbaum, R., & Schaffer, M. (2010). Curcumin as an anticancer agent: Review of the gap between basic and clinical applications. Current Medicinal Chemistry, 17, 190–197.PubMedCrossRefGoogle Scholar
  7. Bayet-Robert, M., Kwiatkowski, F., Leheurteur, M., et al. (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biology & Therapy, 9, 8–14.CrossRefGoogle Scholar
  8. Braumann, C., Guenther, N., Loeffler, L. M, & Dubiel, W. (2009). Liver metastases after colonic carcinoma—palliative chemotherapy plus curcumin. International Journal of Colorectal Disease, 24, 859–860.PubMedCrossRefGoogle Scholar
  9. Cekmen, M., Ilbey, YO., Ozbek, E, et al. (2009). Curcumin prevents oxidative renal damage induced by acetaminophen in rats. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 47, 1480–1484.CrossRefGoogle Scholar
  10. Chainani-Wu, N. (2003). Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). Journal of Alternative and Complementary Medicine (New York, N. Y.), 9, 161–168.CrossRefGoogle Scholar
  11. Chainani-Wu, N., Silverman, S. Jr., Reingold, A., et al. (2007). A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine, 14, 437–446.PubMedCrossRefGoogle Scholar
  12. Chang, K. W., Hung, P. S., Lin, I. Y., et al. (2010). Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression. International Journal of Cancer. Journal International du Cancer, 127, 9–20.PubMedCrossRefGoogle Scholar
  13. Chen, Y., Liu, W. H., Chen, B. L., et al. (2010). Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. The Annals of Pharmacotherapy, 44, 1038–1045.PubMedCrossRefGoogle Scholar
  14. Cheng, A. L., Hsu, C. H., Lin, J. K., et al. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21, 2895–2900.PubMedGoogle Scholar
  15. Cruz-Correa, M., Shoskes, D. A., Sanchez, P., et al. (2006). Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clinical Gastroenterology and Hepatology: The official clinical practice journal of the American Gastroenterological Association, 4, 1035–1038.CrossRefGoogle Scholar
  16. Dance-Barnes, S. T., Kock, N. D., Moore, J. E., et al. (2009). Lung tumor promotion by curcumin. Carcinogenesis, 30, 1016–1023.PubMedCrossRefGoogle Scholar
  17. Deodhar, S. D, Sethi, R., & Srimal, R. C. (1980). Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). The Indian Journal of Medical Research, 71, 632–634.PubMedGoogle Scholar
  18. Dhillon, N., Aggarwal, B. B., Newman, R. A., et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clinical cancer research: An official journal of the American Association for Cancer Research, 14, 4491–4499.CrossRefGoogle Scholar
  19. Eigner, D., & Scholz, D. (1999). Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. Journal of Ethnopharmacology, 67, 1–6.PubMedCrossRefGoogle Scholar
  20. Elwood, P. C., Gallagher, A. M., Duthie, G. G., et al. (2009). Aspirin, salicylates, and cancer. Lancet, 373, 1301–1309.PubMedCrossRefGoogle Scholar
  21. Epelbaum, R., Schaffer, M., Vizel, B., et al. (2010). Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutrition and Cancer, 8, 1137–1141.CrossRefGoogle Scholar
  22. Fryer, R. A., Galustian, C., & Dalgelish, A. G. (2009). Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clinical Pharmacology, 4, 102–112.CrossRefGoogle Scholar
  23. Garcea, G., Berry, D. P., Jones, D. J, et al. (2005). Consumption of putative chemopreventive agent curcumin levels in the colorectum and pharmacodynamic consequences. Cancer Epidemiology, Biomarkers & Prevention: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 14, 120–125.Google Scholar
  24. Goel, A., Boland, C. R., & Chauhan, D. P. (2001). Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Letters, 172, 111–118.PubMedCrossRefGoogle Scholar
  25. Goel, A., Jhurani, S., & Aggarwal, B. B. (2008). Multi-targeted therapy by curcumin: How spicy is it? Molecular Nutrition & Food Research, 52, 1010–1030.CrossRefGoogle Scholar
  26. Hanif, R., Qiao, L., Shiff, S. J., et al. (1997). Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. The Journal of Laboratory and Clinical, 130, 576–584.CrossRefGoogle Scholar
  27. Hatcher, H., Planalp, R., Cho, J., et al. (2008). Curcumin: From ancient medicine to current clinical trials. Cellular and Molecular Life Sciences: CMLS, 65, 1631–1652.PubMedCrossRefGoogle Scholar
  28. Hsu, C. H., & Cheng, A. L. (2007). Clinical studies with curcumin. Advances in Experimental medicine and Biology, 595, 471–480. http://clinicaltrials.gov/ct/search?term_curcumin.Google Scholar
  29. Jagetia, G. C. (2007). Radioprotection and radiosensitization by curcumin. Advances in experimental Medicine and Biology, 595, 301–320.PubMedCrossRefGoogle Scholar
  30. Jiao, Y., Wilkinson, J. 4th., Di, X., et al. (2009). Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood, 113, 462–469.PubMedCrossRefGoogle Scholar
  31. Joe, B., & Lokesh, B. R. (1994). Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochimica et Biophysica Acta, 1224, 255–263.PubMedCrossRefGoogle Scholar
  32. Kang, H. J., Lee, S. H., Price, J. E, et al. (2009). Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. The Breast Journal, 15, 223–229.PubMedCrossRefGoogle Scholar
  33. Kang, J., Chen, J., Shi, Y., et al. (2005). Curcumin-induced histone hypoacetylation: The role of reactive oxygen species. Biochemical Pharmacology, 69, 1205–1213.PubMedCrossRefGoogle Scholar
  34. Kawamori, T., Lubet, R., Steele, V. E., et al. (1999). Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Research, 59, 597–601.PubMedGoogle Scholar
  35. Khopde, S., Priyadarsini, K. I., Venkatesan, P., et al. (1999). Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophysical Chemistry, 80, 85–91.CrossRefGoogle Scholar
  36. Kunnumakkara, A. B., Diagaradjane, P., Anand, P., et al. (2009). Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. International Journal of Cancer. Journal International du Cancer, 125, 2187–2197.PubMedCrossRefGoogle Scholar
  37. Kunwar, A., Sandur, S. K., Krishna, M., et al. (2009). Curcumin mediates time and concentration dependent regulation of redox homeostasis leading to cytotoxicity in macrophage cells. European Journal of Pharmacology, 611, 8–16.PubMedCrossRefGoogle Scholar
  38. Kuttan, R., Bhanumathy, P., Nirmala, K., et al. (1985). Potential anticancer activity of turmeric (Curcuma longa). Cancer Letters, 29, 197–202.PubMedCrossRefGoogle Scholar
  39. Kuttan, R., Sudheeran, P. C., & Josph, C. D. (1987). Turmeric and curcumin as topical agents in cancer therapy. Tumori, 73, 29–31.PubMedGoogle Scholar
  40. Lampe, V., & Milobedzka, J. (1913) Studien über Curcumin. Berichte der deutschen chemischen Gesellschaft, 46, 2235–2240.CrossRefGoogle Scholar
  41. Lee, J. C., Kinniry, P. A., Arguiri, E., et al. (2010). Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiation Research, 173, 590–601.PubMedCrossRefGoogle Scholar
  42. Lev-Ari, S., Lichtenberg, D., & Arber, N. (2008). Compositions for treatment of cancer and inflammation. Recent Patents on Anticancer Drug Discovery, 3, 55–62.Google Scholar
  43. Li, L., Braiteh, F. S., & Kurzrock, R. (2005). Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer, 104, 1322–1331.PubMedCrossRefGoogle Scholar
  44. Lin, S. S., Lai, K. C., Hsu, S. C, et al. (2009). Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Letters, 285, 127–133.PubMedCrossRefGoogle Scholar
  45. López-Lázaro, M. (2008). Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Molecular Nutrition & Food Research, 52(Suppl. 1), S103–S127.Google Scholar
  46. Mahmoud, N. N., Carothers, A. M., Grunberger, D., et al. (2000). Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis, 21, 921–927.PubMedCrossRefGoogle Scholar
  47. Mendonça, L. M., Dos, Santos, G. C., Antonucci, G. A., et al. (2009). Evaluation of the cytotoxicity and genotoxicity of curcumin in PC12 cells. Mutation Research, 675, 29–34.PubMedCrossRefGoogle Scholar
  48. NCI, D. (1996). Clinical development plan: Curcumin. Journal of Cellular Biochemistry. Supplement, 26, 72–85.Google Scholar
  49. Oppenheimer, A. (1937). Tumeric (curcumin) in biliary diseases. Lancet, 229, 619–621.CrossRefGoogle Scholar
  50. Padhye, S., Banerjee, S., Chavan, D., et al. (2009). Fluorocurcumins as cyclooxygenase-2 inhibitor: Molecular docking, pharmacokinetics and tissue distribution in mice. Pharmaceutical Research, 26, 2438–2445.PubMedCrossRefGoogle Scholar
  51. Park, J., Ayyappan, V., Bae, E. K., et al. (2008). Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Molecular Oncology, 2, 317–326.PubMedCrossRefGoogle Scholar
  52. Patel, B. B., Gupta, D., Elliott, A. A., et al. (2010). Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Research, 30, 319–325.PubMedGoogle Scholar
  53. Plummer, S. M., & Holloway, K. A., (1999). Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 18, 6013–6020.PubMedCrossRefGoogle Scholar
  54. Reddy, S., Rishi, A. K., Xu, H., et al. (2006). Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutrition and Cancer, 55, 185–194.PubMedCrossRefGoogle Scholar
  55. Samaha, H. S., Kelloff, G. J., Steele, V., et al. (1997). Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Research, 57, 1301–1305.PubMedGoogle Scholar
  56. Shahani, K., Swaminathan, S. K., Freeman, D., et al. (2010). Injectable sustained release microparticles of curcumin: A new concept for cancer chemoprevention. Cancer Research, 70, 4443–4452.PubMedCrossRefGoogle Scholar
  57. Shankar, T., Shantha, N. V., Ramesh, H. P., et al. (1980). Toxicity studies on turmeric (Curcuma longa): Acute toxicity studies in rats, guinea pigs and monkeys. Indian Journal of Experimental Biology, 18, 73–75.PubMedGoogle Scholar
  58. Sharma, R. A., Euden, S. A., Platton, S. L., et al. (2004). Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clinical cancer research: An official journal of the American Association for Cancer Research, 10, 6847–6854.CrossRefGoogle Scholar
  59. Sharma, R. A., McLelland, H. R., Hill, K. A., et al. (2001). Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clinical cancer research: An official journal of the American Association for Cancer Research, 7, 1894–1900.Google Scholar
  60. Sou, K., Inenaga, S., Takeoka, S., et al. (2008). Loading of curcumin into macrophages using lipid-based nanoparticles. International Journal of Pharmaceutics, 352, 287–293.PubMedCrossRefGoogle Scholar
  61. Strimpakos, A. S., & Sharma, R. A. (2008). Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants & Redox Signaling, 10, 511–545.CrossRefGoogle Scholar
  62. Sung, B., Kunnumakkara, A. B., Sethi, G., et al. (2009). Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Molecular Cancer Therapeutics, 8, 959–970.PubMedCrossRefGoogle Scholar
  63. Tharakan, S. T., Inamoto, T., Sung, B., et al. (2010). Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochemical Pharmacology, 79, 218–228.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Division of Oncology, Rambam-Health Care Campus and Faculty of MedicineTechnion-Israel Institute of TechnologyHaifaIsrael

Personalised recommendations